drugset
drugset / Trial / NCT06371638

Dexmedetomidine and Postoperative Cognitive Dysfunction (POCD)

NCT06371638 ↗

Phase 4 Completed 112 enrolled Udayana University
RandomizedParallel-groupSingle-blindPrevention

Summary

Postoperative cognitive dysfunction (POCD) affects all age groups and can lead to increased morbidity and more extended hospital stays. Dexmedetomidine reduces POCD by inhibiting the increase in proinflammatory cytokines IL-6 and TNF-α, and its anti-inflammatory activity contributes to its protective effect. Previous studies found that dexmedetomidine reduced POCD incidence in non-cardiac and cardiac surgery. Therefore, the goal of this study was to specifically investigate if using TCI dexmedetomidine to maintain anaesthesia in laparotomy surgeries reduces the incidence of POCD compared to inhalation anaesthesia by sevoflurane.

Timeline

Start
2024-01-07
Primary completion
2024-03-01
Completion
2024-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 1 ng/ml —
Subject Sevoflurane Other / unclassified 0.8 % Inhaled

Indications

No indication recorded.